Detalhe da pesquisa
1.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
N Engl J Med
; 386(5): 437-448, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045221
2.
Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.
J Pathol
; 262(2): 129-136, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38013631
3.
Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.
Cancer
; 130(4): 576-587, 2024 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37886874
4.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523661
5.
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Gynecol Oncol
; 182: 75-81, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262242
6.
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series.
Int J Gynecol Cancer
; 34(4): 594-601, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38296517
7.
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Cancer Immunol Immunother
; 72(1): 183-191, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779095
8.
HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
Mod Pathol
; 36(11): 100299, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37558129
9.
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations.
Gynecol Oncol
; 174: 148-156, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207499
10.
Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinoma.
Gynecol Oncol
; 175: 8-14, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37267674
11.
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Gynecol Oncol
; 178: 27-35, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37748268
12.
Isolated vaginal recurrence in women with stage I endometrial cancer.
Gynecol Oncol
; 179: 9-15, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864854
13.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Gynecol Oncol
; 169: 64-69, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512912
14.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol
; 178: 110-118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839313
15.
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Gynecol Oncol
; 174: 262-272, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37245486
16.
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol
; 174: 34-41, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149903
17.
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer.
J Natl Compr Canc Netw
; 21(2): 217-226, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791759
18.
Endometrial carcinosarcoma.
Int J Gynecol Cancer
; 33(2): 147-174, 2023 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36585027
19.
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Cancer Sci
; 113(10): 3489-3497, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35612971
20.
Impact of obesity and white adipose tissue inflammation on the omental microenvironment in endometrial cancer.
Cancer
; 128(18): 3297-3309, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35793549